Back to top
more

Quest Diagnostics (DGX)

(Delayed Data from NYSE)

$153.95 USD

153.95
499,931

-1.30 (-0.84%)

Updated Oct 1, 2024 04:00 PM ET

After-Market: $153.88 -0.07 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (49 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

ResMed's (RMD) Q4 Earnings Surpass Estimates, Margins Expand

ResMed (RMD) delivers solid performance across all regions and business segments in the fourth quarter of fiscal 2024.

Mark Vickery headshot

Labcorp (LH) Q2 Earnings Surpass Estimates (revised)

Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.

BD (BDX) Q3 Earnings Surpass Estimates, Margins Expand

BD's (BDX) overall topline benefits from revenue growth in all segments in the fiscal third quarter.

Avanos (AVNS) Q2 Earnings Top Estimates, Gross Margin Contracts

Strength in Avanos' (AVNS) Digestive Health segment drives its second-quarter performance.

CONMED (CNMD) Q2 Earnings Beat, Sales Rise Y/Y, '24 View Cut

CONMED (CNMD) beats second-quarter earnings estimates on the back of higher revenues and lower costs and expenses. However, the result reflects the continued impact of supply chain issues.

Labcorp (LH) Q2 Earnings Surpass Estimates, Margins Increase

Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.

QIAGEN (QGEN) Q2 Earnings Surpass Estimates, Margins Crash

QIAGEN's (QGEN) earnings and revenues beat estimates in the second quarter. The company remains bullish on solid growth trends in the core business.

Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, Encompass Health and Addus HomeCare

Quest Diagnostics, DaVita, Encompass Health and Addus HomeCare have been highlighted in this Industry Outlook article.

Stryker's (SYK) Q2 Earnings Beat Estimates, Guidance Raised

Stryker (SYK) beats second-quarter earnings estimates, driven by robust sales growth and innovative launches like the LIFEPAK 35 and Spine Guidance 5. The company raises 2024 guidance.

Debanjana Dey headshot

4 Stocks to Watch From a Challenging Outpatient Home Health Industry

Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, EHC and ADUS are well-poised to gain.

Penumbra (PEN) Tops on Q2 Earnings, Lowers Sales View

Penumbra's (PEN) Thrombectomy product category shows encouraging growth trends, reflecting strong momentum in CAVT products.

Neogen (NEOG) Q4 Earnings Miss Estimates, Margins Crash

Neogen's (NEOG) Food Safety and Animal Safety businesses witness a year-over-year decrease in revenues in the fourth quarter of fiscal 2024.

Integra's (IART) Q2 Earnings and Revenues Top, Margins Down

Integra's (IART) second-quarter 2024 results reflect strong demand for its diverse portfolio of leading brands and the continued successful market adoption of CereLink.

Baxter's (BAX) Helion Surgical System Debuts in Thailand

Baxter (BAX) launches the Helion Integrated Surgical System in Thailand, aiming to streamline operating room efficiency and enhance surgical team connectivity with cutting-edge technology.

DGX vs. PNTG: Which Stock Is the Better Value Option?

DGX vs. PNTG: Which Stock Is the Better Value Option?

Hologic (HOLX) Q3 Earnings Surpass Estimates, Margins Rise

Hologic (HOLX) delivers strong performances across all its franchises in the third quarter of fiscal 2024.

Avantor's (AVTR) Q2 Earnings Beat, Operating Margin Declines

Avantor's (AVTR) revenues decline in the second quarter with new segmental changes. Bioprocessing orders decline. Operating margin contracts.

Are Investors Undervaluing Quest Diagnostics (DGX) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Integer Holdings (ITGR) Q2 Earnings Top Estimates, Margins Up

Integer Holdings' (ITGR) second-quarter results reflect robust Medical Sales, along with strength in all the product lines.

DexCom's (DXCM) Q2 Earnings Beat Estimates, Revenues Miss

DexCom's (DXCM) second-quarter 2024 earnings surpass expectations while revenues fall short. The Sensor segment and CGM system expansion drive growth. Shares fall.

Hologic (HOLX) Buys Endomag to Boost Breast Cancer Solutions

Hologic (HOLX) acquires Endomag for $310M, enhancing its breast cancer surgery portfolio with innovative technologies like Magseed and Magtrace, aiming to improve patient care and outcomes globally.

Amedisys (AMED) Q2 Earnings Top Estimates, Gross Margin Down

Amedisys (AMED) delivers year-over-year growth in all three of its segmental revenues in the second quarter of 2024.

Terumo (TRUMY) Unit Reveals WEB 17 Device Effective in Aneurysms

Terumo's (TRUMY) subsidiary MicroVention's WEB 17 device, used in treating intracranial aneurysms, demonstrates high safety and effectiveness in the CLEVER study.

Edwards Lifesciences (EW) Q2 Earnings Meet Mark, Margins Crash

Edwards Lifesciences (EW) reports strong contributions from the TMTT product group in the second quarter of 2024.

Chemed (CHE) Q2 Earnings Miss Estimates, Margins Expand

Chemed's (CHE) VITAS segment delivers impressive revenue growth and margin expansion in the second quarter of 2024.